TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of SRP-4053 in DMD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with DMD, genotypically confirmed.~* Intact right and left biceps muscles or an alternative upper arm muscle group.~* Stable pulmonary and cardiac function.~* Minimum performance on 6MWT, North Star Ambulatory Assessment, and rise (Gowers) test as specified in the study protocol.~* On a stable dose of corticosteroids for at least 6 months.~Exclusion Criteria:~* Previous treatment with the experimental agents BMN-195 (SMT C1100) or PRO053.~* Current or previous treatment with any other experimental treatments within 12 weeks prior to study entry.~* Major surgery within the last 3 months.~* Presence of other clinically significant illness.~* Major change in physical therapy regime within the last 3 months.~Other inclusion and exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: SRP-4053 (Type: EXPERIMENTAL): Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
- Part 2: SRP-4053 (Type: EXPERIMENTAL): All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
- Part 2: Untreated Group (Type: NO_INTERVENTION): Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic \[PK\] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index must be between 18.0 kg/m2 and ≤ 31.5 kg/m2;~* Non-smokers for at least 3 months preceding screening;~* Females subjects must be of non-childbearing potential e.g., post-menopausal or pre-menopausal with surgical sterilization;~* Males agree to use appropriate contraception;~* Medical history must be verified by either a personal physician or medical practitioner as appropriate;~* Willing to give written informed consent and are willing to comply with the study requirements.~Exclusion Criteria:~* Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection~* Multiple drug allergies or know sensitivity to oligonucleotide~* History of drug abuse and/or alcohol abuse~* Receiving an investigational agent within 3 months prior to study drug administration~* Subjects with safety laboratory test results deemed clinical significant by the Investigator;~* Received prescription drugs within 4 weeks of first dosing~* Subjects who have donated more than 500 mL of blood within the 3 months prior to ALN-PCS02 or placebo administration;~* Subjects who have used prescription drugs within 4 weeks of first dosing~* Considered unfit for the study by the Principal Investigator~* Employee or family member of the sponsor or the clinical study site personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ALN-TTR02 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of 5 Years of GH Replacement on Atherosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male gender~* age \<50 yrs to limit the effect of aging;~* body mass index \<30 Kg/m2;~* no familial or personal history of cardiovascular diseases;~* no concomitant treatment with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure at the time of study entry;~* no previous GH treatment~Exclusion Criteria:~* female gender~* age \>50 yrs;~* body mass index ≥30;~* familial or personal history of cardiovascular diseases;~* previous and present treatments with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure;~* previous GH treatment in adult age~* GHD of childhood onset~* GHD due to previous Cushing's disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who participated in main double-blind induction study C87037 (NCT00291668) and showed clinical efficacy~Exclusion Criteria:~* Subjects who experienced aggravation of Crohn's disease during main double-blind induction study C87037 (NCT00291668) and required treatment change

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CZP 400 mg / Placebo (Type: EXPERIMENTAL): Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
- CZP 400 mg / CZP 200 mg (Type: EXPERIMENTAL): Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
- CZP 400 mg / CZP 400 mg (Type: EXPERIMENTAL): Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for at least 6 months before the first administration of study drug~* Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (\>=) 12 at Screening and at Baseline~* Have an Investigator's Global Assessment (IGA) \>=3 at Screening and at Baseline~* Have an involved body surface area (BSA) \>= 10 percent (%) at Screening and at Baseline~* Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment)~Exclusion Criteria:~* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances~* Has unstable cardiovascular disease, defined as a recent clinical deterioration (example \[eg\], unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months~* Currently has a malignancy or has a history of malignancy within 5 years before Screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration, or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study drug administration)~* Has previously received guselkumab or ustekinumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Open-label ustekinumab (Type: EXPERIMENTAL): None
- Double-blind guselkumab (Type: EXPERIMENTAL): None
- Double-blind ustekinumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-centre Failed Bowel Prep RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Anyone undergoing a repeat colonoscopy due to failed bowel preparation at index colonoscopy. Failure is defined as preparation quality inadequate to detect lesions \> 5 mm after washing and requiring a shortened colonoscopy interval as a result.~2. Age \> 18 years~3. Outpatient colonoscopy~4. Indication for full colonoscopy~Exclusion Criteria:~1. Subject refusal~2. Able to comprehend the trial~3. Index colonoscopy performed as an inpatient~4. Pregnancy or breastfeeding~5. Allergies to the employed bowel preparations~6. Any colonic surgery~7. History of ischemic colitis~8. Congestive heart failure~9. Chronic renal failure~10. Cirrhosis~11. Severe electrolyte imbalance~12. Non-adherence to index bowel preparation defined as failure to follow diet instructions and/or consume the entire volume of bowel preparation medication as prescribed for any reason (ex. eating a normal diet on the day of colonoscopy, PEG intolerance, etc...)~13. Use of bowel preparation in an off-label manner for the index colonoscopy.~14. Inability to follow verbal and written instructions in English or French.~15. Ileus, gastric outlet obstruction, gastrointestinal obstruction, bowel preforation~16. Toxic coitis or toxic megacolon~17. Acute surgical abdomen including appendicitis~18. Gastroenteritis and acute diverticulitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen A (Type: EXPERIMENTAL): 4L PegLyte + 15 mg bisacodyl
- Regimen B (Type: EXPERIMENTAL): 6L PegLyte + 15 mg bisacodyl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* (1) HIV treatment-naïve, (2) age between 18 years or older, (3) be willing to complete the HAMD and PSQI scale and follow-up regularly, (5) not participating in other studies.~Exclusion Criteria:~* (1) acute HIV-1-infected patients, (2) an AIDS-defining illness such as pneumocystis pneumonia, tuberculosis within 2 weeks of entry, (3) transaminase and alkaline phosphatase levels beyond three times the upper limit of the normal range, bilirubin level more than 2.5 times the upper limit of the normal range, and serum creatinine level excess 1.5 times the upper limit of the normal range, (4) pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Efavirenz 400mg+TDF+3TC (Type: EXPERIMENTAL): Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 25 y/o~* No occurrence of intra- or post-operative cardiopulmonary arrest~* Not consuming drugs affecting atrial rhythm~* Having sinus rhythm before surgery~* Lack of paroxysmal atrial fibrillation history~* Only undergo heart valve surgery~* Lack of considerable heart ischemia needed atorvastatin use~* Routine cares in ward, post-operative ward, and intensive care unit were done~Exclusion Criteria:~* Lesser than 25 y/o~* History of atrial fibrillation~* History of taking anti-arrhythmic drugs~* History of implementing pacemakers~* Severe heart failure~* Renal failure~* Hepatic failure~* Severe pulmonary diseases~* Heart block or bradyarrhythmia~* Routine cares in ward, post-operative ward, and intensive care unit were not done~* Performing concomitant cardiac surgery except valve repair~* Having considerable heart ischemia needed atorvastatin use

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
- Control (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Cannabis Use for Sleep Among Adults Using Medical Cannabis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 years or older~* Insomnia Severity Index (ISI) score greater than 10 (indicating mild insomnia),~* Use of cannabis on average three times a week for the past three months,~* Self-reported use of cannabis to manage insomnia at least once a week over the past month,~* Positive drug screen for Tetrahydrocannabinol (THC),~* Consistent access to a telephone, smart phone, laptop, or tablet~Exclusion Criteria:~* Individuals who do not understand English,~* Individuals judged unable to provide informed consent (e.g. intoxication, mental incompetence),~* Diagnosis or high suspicion of a sleep disorder based on validated self-report questionnaires,~* Self-reported cancer,~* Self-reported pregnancy,~* Self-reported rotating or night (3rd) shift work.~* Participants taking medications for sleep will be included if they meet study criteria for insomnia, medications have been stable for at least 8 weeks, and they agree to maintain the same regimen throughout the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB) (Type: EXPERIMENTAL): None
- Sleep Hygiene Education (SHE) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ilaris (Canakinumab) in the Schnitzler Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active Schnitzler syndrome after withdrawal of anakinra or tapering of corticosteroids.~* Male and female patients at least 18 years of age at the time of screening visit.~* Signed patient informed consent~* Negative QuantiFERON test or negative Purified Protein Derivative (PPD) test (\<5 mm induration) at screening or within 1 month prior to the screening visit, according to Belgium guidelines. Patients with a positive PPD test (=5 mm induration) at screeninig may be enrolled only if they have a negative chest x-ray or negative QuantiFERON test (QFT-TB G In-Tube).~* Adequate contraception in females of childbearing potential.~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot)~* Serologic evidence of active hepatitis B or C infection~* Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.~* History of significant medical conditions, which in the investigator's opinion would exclude the patient from participating in this trial.~* History of recurrent and/or evidence of active bacterial, fungal or viral infection(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): * Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with hepatitis C genotype 1 or mixed hepatitis C genotype;~* Asymptomatic or nearly asymptomatic from hepatitis C;~* Previous therapy with interferon and ribavirin or peginterferon and ribavirin without an SVR or relapsed following an SVR;or Interferon naive subjects~* Chronically infected (at least 6 months since diagnosis) HCV-positive subjects;~* No evidence of bridging necrosis or cirrhosis;~* Liver biopsy within the last 2 years~Exclusion Criteria:~* Acute hepatitis C infection~* History of prior malignancy, acquired or inherited immunodeficiency or autoimmune disease either documented or anecdotal;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Compensated chronic hepatitis B patient~* Presence of serum HBsAg for more than 6 months.~* Presence of HBeAg for more than 1 month with compensated liver disease~* Confirmation of YMDD mutants (M552V, M552I and its related double mutant at L528M) by genotyping of the YMDD motif using line probe assay (INNO-LiPA HBV DR assay)~* Screening HBV DNA value higher than or equal to 1,000,000 copies/mL (measured by the COBAS Amplicor HBV Monitor™ assay)~* Screening ALT value between 1.5 and 10 x ULN~Exclusion Criteria:~* Co-infection with hepatitis C or D virus (HCV or HDV) or HIV~* Pregnancy or breast-feeding~* Previous treatment with nucleoside analogue or any other treatment for HBV except for lamivudine within 6 months prior to study entry~* Treatment with immunomodulatory agent or corticosteroids within 6 months prior to study entry.~* De-compensated liver disease~* Screening alpha-fetoprotein (AFP) value \> 20 ng/mL, and a follow-up ultrasonography performed prior to baseline shows findings indicative of HCC.~* Presence of anti-HBs at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LB80380 30mg (Type: EXPERIMENTAL): LB80380 30mg
- LB80380 60mg (Type: EXPERIMENTAL): LB80380 60mg
- LB80380 90mg, (Type: EXPERIMENTAL): LB80380 90mg
- LB80380 150mg (Type: EXPERIMENTAL): LB80380 150mg
- LB80380 240mg (Type: EXPERIMENTAL): LB80380 240mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete